Table 4.

Effect of APG on the frequency of SCEs per cell, range of SCE, PRI and percent inhibition in human lymphocytes treated in vitro with MMC

Donor	Endpoint	Control	APG	MMC	APG + MMC	(b + c) – a = x	x – y = z	% inhibition
		a	b	c	y Observed	Expected		z/x*100
1	SCE	4.56 ± 0.344	9.30 ± 0.500	29.88 ± 0.928	29.00 ± 1.106	34.62*	5.62	16.23
	Range	1–10	4–20	16–48	6–45
	PRI	2.50	2.13	2.40	2.01
2	SCE	5.34 ± 0.371	10.18 ± 0.484	38.78 ± 1.344	37.02 ± 1.030	43.62*	6.60	15.13
	Range	1–12	3–19	18–64	22–58
	PRI	2.57	1.88	1.91	1.74
3	SCE	4.84 ± 0.367	9.36 ± 0.534	49.32 ± 1.546	35.42 ± 1.143	53.84*	18.42	34.21
	Range	0–10	3–22	31–71	18–53
	PRI	2.20	2.01	2.07	1.68
4	SCE	5.52 ± 0.406	8.64 ± 0.531	45.78 ± 0.957	36.26 ± 1.088	48.90*	12.64	25.85
	Range	1–17	3–18	34–63	22–60
	PRI	2.22	2.05	2.03	1.77
5	SCE	6.12 ± 0.408	9.68 ± 0.522	45.30 ± 1.314	34.24 ± 0.999	48.86*	14.62	29.92
	Range	0–13	3–18	32–70	23–58
	PRI	2.33	2.09	1.78	1.70
6	SCE	5.32 ± 0.453	10.02 ± 0.519	83.50 ± 2.137	73.26 ± 2.584	88.20**	14.94	16.94
	Range	2–17	2–21	58–110	43–108
	PRI	2.14	2.07	1.38	1.68

50 second-division metaphases scored for SCEs. 200 cells scored to determine PRI, *P < 0.01 (first 5 donors).